Stoke Therapeutics, Inc. (STOK) Ownership
STOK ownership summary
as of October 18, 2026- Institutions
- 125.4% of shares outstanding
- Insiders
- 3.68% of shares outstanding
- Shares outstanding
- 64.5M
- Float
- 45.6M shares available to trade
- Short interest
- 18.52% 11.5M shares short
- Days to cover
- 12.49 short interest up 3.2% vs prior month
- Institutions 125.45%
- Insiders 3.68%
STOK top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 9.11% | 5.9M | $142.1M | +491,643 (+9.1%) | June 30, 2026 |
| 2 | RTW INVESTMENTS, LLC | 8.72% | 5.6M | $135.9M | — | June 30, 2026 |
| 3 | FMR Inc | 8.23% | 5.3M | $128.4M | −70,566 (−1.3%) | June 30, 2026 |
| 4 | Lynx1 Capital Management, LP | 6.26% | 4.0M | $97.6M | −725,269 (−15.2%) | June 30, 2026 |
| 5 | Redmile Group, LLC | 6.12% | 3.9M | $95.4M | −218,200 (−5.2%) | June 30, 2026 |
| 6 | Wellington Management Company LLP | 5.45% | 3.5M | $85.1M | +423,601 (+13.7%) | June 30, 2026 |
| 7 | Morgan Stanley - Brokerage Accounts | 5.35% | 3.5M | $83.5M | +29,515 (+0.9%) | June 30, 2026 |
| 8 | Baker Bros Advisors LP | 5.17% | 3.3M | $80.6M | — | June 30, 2026 |
| 9 | The Toronto-Dominion Bank | 4.92% | 3.2M | $76.7M | — | June 30, 2026 |
| 10 | State Street Corp | 4.42% | 2.9M | $68.9M | +575,728 (+25.3%) | June 30, 2026 |
| 11 | T. Rowe Price Associates, Inc. | 4.12% | 2.7M | $64.3M | +727,568 (+37.6%) | June 30, 2026 |
| 12 | Vanguard Capital Management, LLC | 4.01% | 2.6M | $62.5M | +231,334 (+9.8%) | June 30, 2026 |
| 13 | Bvf Inc | 3.95% | 2.5M | $61.6M | — | June 30, 2026 |
| 14 | T. Rowe Price Investment Management,Inc. | 3.74% | 2.4M | $58.4M | +2.2M (+862.5%) | June 30, 2026 |
| 15 | Assenagon Asset Management SA | 3.50% | 2.3M | $54.5M | +1.3M (+148.8%) | June 30, 2026 |
| 16 | Siren, L.L.C. | 3.09% | 2.0M | $48.2M | — | June 30, 2026 |
| 17 | Deerfield Management Co | 2.83% | 1.8M | $44.1M | — | June 30, 2026 |
| 18 | Jupiter Topco LLC | 2.81% | 1.8M | $43.9M | +1.8M (0.0%) | June 30, 2026 |
| 19 | HHG PLC | 2.50% | 1.6M | $39.0M | +161,848 (+11.2%) | March 31, 2026 |
| 20 | Geode Capital Management, LLC | 2.36% | 1.5M | $36.8M | +202,049 (+15.3%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 8.2M shares and 3 cut 1.0M.
STOK top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.93% | 1.9M | $45.7M | −3,561 (−0.2%) | August 31, 2026 |
| 2 | Vanguard Health Care Inv | 2.84% | 1.8M | $44.2M | +177,438 (+10.7%) | June 30, 2026 |
| 3 | Fidelity Select Biotechnology | 2.30% | 1.5M | $35.8M | +19,500 (+1.3%) | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 2.21% | 1.4M | $34.5M | −16,448 (−1.1%) | September 30, 2026 |
| 5 | RTW Biotech Opportunities Ord | 2.19% | 1.4M | $34.1M | +953,780 (+208.6%) | December 31, 2025 |
| 6 | State Street® SPDR® S&P® Biotech ETF | 2.05% | 1.3M | $31.9M | −25,250 (−1.9%) | September 30, 2026 |
| 7 | Polar Capital Biotech S Inc | 1.22% | 790K | $19.1M | — | August 31, 2026 |
| 8 | T. Rowe Price New Horizons | 1.03% | 664K | $16.1M | −27,136 (−3.9%) | August 31, 2026 |
| 9 | Fidelity Select Health Care | 0.97% | 628K | $15.2M | — | August 31, 2026 |
| 10 | Fidelity Small Cap Index | 0.93% | 602K | $14.6M | +5,304 (+0.9%) | July 31, 2026 |
| 11 | Fidelity Small Cap Growth | 0.81% | 521K | $12.6M | — | July 31, 2026 |
| 12 | iShares Russell 2000 Growth ETF | 0.80% | 516K | $12.5M | −653 (−0.1%) | September 30, 2026 |
| 13 | Candriam Eqs L Biotech C USD Cap | 0.78% | 502K | $12.1M | — | March 31, 2026 |
| 14 | T. Rowe Price Integrated US Sm Gr Eq | 0.77% | 496K | $12.0M | — | August 31, 2026 |
| 15 | BlackRock Health Sciences Opps Inv A | 0.73% | 473K | $11.4M | — | August 31, 2026 |
| 16 | Fidelity Stock Selector Small Cap | 0.67% | 435K | $10.5M | — | July 31, 2026 |
| 17 | T. Rowe Price Small-Cap Stock | 0.65% | 421K | $10.2M | −27,280 (−6.1%) | August 31, 2026 |
| 18 | iShares Biotechnology ETF | 0.65% | 417K | $10.1M | −3,160 (−0.8%) | September 30, 2026 |
| 19 | BGF World Healthscience A2 | 0.60% | 385K | $9.3M | — | June 30, 2026 |
| 20 | Schwab US Small-Cap ETF™ | 0.53% | 340K | $8.2M | +225 (+0.1%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
STOK insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-19 | Barry Ticho | Sell | $29.99 | 1,461 | $43,815 |
| 2026-03-18 | Thomas Leggett | Sell | $31.34 | 2,382 | $74,652 |
| 2026-03-18 | Jonathan Allan | Sell | $31.34 | 4,628 | $145,042 |
| 2026-03-18 | Jason Hoitt | Sell | $31.34 | 1,931 | $60,518 |
| 2026-03-18 | Barry Ticho | Sell | $31.34 | 6,686 | $209,539 |
| 2026-03-17 | Barry Ticho | Sell | $33.01 | 6,164 | $203,474 |
| 2026-03-17 | Jason Hoitt | Sell | $33.01 | 1,781 | $58,791 |
| 2026-03-17 | Jonathan Allan | Sell | $33.01 | 4,267 | $140,854 |
| 2026-03-17 | Thomas Leggett | Sell | $33.01 | 2,196 | $72,490 |
| 2026-03-13 | Arthur A Levin | Sell | $36.80 | 605 | $22,264 |
| 2026-03-10 | Adrian R Krainer | Sell | $39.74 | 33,243 | $1.3M |
| 2026-03-10 | Arthur Tzianabos | Sell | $40.00 | 4,355 | $174,200 |
| 2025-12-08 | Edward M Md Kaye | Sell | $32.27 | 13,430 | $433,386 |
| 2025-12-08 | Jonathan Allan | Sell | $32.28 | 3,978 | $128,410 |
| 2025-12-05 | Barry Ticho | Sell | $31.34 | 3,662 | $114,767 |
| 2025-12-05 | Edward M Md Kaye | Sell | $31.32 | 8,548 | $267,723 |
| 2025-12-05 | Jonathan Allan | Sell | $31.29 | 8,785 | $274,883 |
| 2025-12-04 | Barry Ticho | Sell | $30.87 | 1,696 | $52,356 |
| 2025-12-04 | Jonathan Allan | Sell | $30.87 | 1,018 | $31,426 |
| 2025-12-04 | Edward M Md Kaye | Sell | $30.87 | 6,453 | $199,204 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
STOK shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns STOK
Institutional investors own 125.4% of Stoke Therapeutics's shares and insiders 3.68%. The largest holder is BlackRock Inc with 9.11% of the shares (5.9M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 3 reduced their stake in the latest filings. Short interest is 18.52% of the float, or 12.49 days of average trading volume. The share count rose 148.3% since 2018.
Related: STOK analyst forecast, STOK key metrics. See the STOK stock overview for the latest quote and news.
STOK ownership FAQ
Who owns the most Stoke Therapeutics stock?
The largest shareholders of Stoke Therapeutics are BlackRock Inc (9.11%), RTW INVESTMENTS, LLC (8.72%), FMR Inc (8.23%), Lynx1 Capital Management, LP (6.26%), Redmile Group, LLC (6.12%).
What percentage of Stoke Therapeutics is owned by institutions?
Institutions hold 125.4% of Stoke Therapeutics's shares outstanding; insiders hold 3.68%.
Which funds own Stoke Therapeutics?
The largest fund holders of Stoke Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.93%), Vanguard Health Care Inv (2.84%), Fidelity Select Biotechnology (2.30%), iShares Russell 2000 ETF (2.21%), RTW Biotech Opportunities Ord (2.19%).
What is Stoke Therapeutics's short interest?
11.5M shares of Stoke Therapeutics were sold short, 18.52% of the float; at the average daily volume it would take 12.49 days to cover.
Are insiders buying or selling Stoke Therapeutics?
Of the latest 20 reported insider transactions in Stoke Therapeutics (since December 4, 2025), 0 were purchases and 20 were sales.
How many shares of Stoke Therapeutics are outstanding?
Stoke Therapeutics has 64.5M shares outstanding, of which 45.6M are in the public float.